Cruz GE, García GRM, Lamotte CJA, Fernández AK

Language: Spanish
References: 16
Page: 102-109
PDF size: 62.51 Kb.

ABSTRACT

Introduction: antiretroviral therapy has had a great impact on the quality of life of people living with HIV/AIDS, but these drugs require strict surveillance due to their toxic effects.
Methods: a study was conducted of 50 HIV/AIDS patients under antiretroviral treatment cared for at Dr. Juan Bruno Zayas hospital from May to September 2011. Determination was performed of variations in hematochemical parameters, including lipid profiles and hematological and renal studies.
Results: most alterations in lipids were found in patients from the Rescue scheme. All schemes showed alterations in total proteins and microalbuminuria, whereas most patients in Schemes 4, 1 and Rescue had anemia. The patients studied presented moderate alterations of the parameters analyzed.
Conclusions: toxicity of the treatments applied is below that reported by other studies.

REFERENCES

1. Lozano F, Viciana P. Efectos adversos del tratamiento antirretrovírico: importancia y espectro clínico. Efectos adversos del tratamiento antirretrovírico. Madrid: Scientific Communication Management, S.L.; 2003. p. 11-8.

2. Moreno C, Rubio Garcia R, Barros Aguado C. Nuevos fármacos antirretrovirales inhibidores del CCR5 y de la integrasa. Rev Clin Esp.2008;208(09):463-6 09.

3. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 2000;356: 1423-30.

4. Encinas de la Iglesia J, Pérez García ML, Fuertes Martín A. Efectos secundarios del tratamiento antirretroviral. FMC 2002;9:343-9.

5. Ministerio de Salud Pública (MINSAP). Manual de Organización hospitalaria. Centro de aseguramiento medico. Laboratorio clínico.2011. Código P06 008.

6. Andrade M, Andrade H. Alteraciones del metabolismo lipídico en pacientes seropositivos para VIH con tratamiento retroviral altamente efectivo. Revista Cubana de Cardiología 2010;16(1):64-73.

7. Roca B. Trastornos metabólicos relacionados con el VIH y el tratamiento antirretroviral. Anales de. Medicina Interna 2003;20 (11):585-93.

8. Smart EJ, Mateev S, Kincer J, Greenberg RN. Protease inhibitors upregulate SR-BI and HDL-dependent colesterol uptake in human macrophages: a mechanism that may enhance foam cell formation. Program and abstracts of the 8th Conference on Retroviruses and Opportunistics Infections; February 4-8, 2001; Chicago, Illinois, Abstract 662

9. San Martin M. HIV and HAART: cardiovascular repercussion. Nutr Metabol Disord HIV Infect 2002; 1: 5-13.

10. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000; (Supl. 2):96-116.

11. Levine AM, Karim R, Mack W, Gravink DJ, Anastas K, Young M, et al. Neutropenia in human immunodeficiency virus infection. Arch Inter Med 2006;166:387.

12. Linares E, Bencomo F, Pérez L. Influencia de la infección por VIH/SIDA sobre algunos indicadores bioquímicos del estado nutricional. Revista Cubana Aliment Nutr 2002;16(2):119-26.

13. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi Lepri A, et al. Reasons for modification and discontinuation of antiretrovirals: results for a single treatment centre. AIDS 2001;15:185-94.

14. Broder, S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic 2009. Antiviral research; 85:1-2.

15. Hernández, J. Microalbuminuria y proteinuria en mujeres con VIH. [acceso: 8 de mayo de 2013]. Disponible en: gtt.vih.org/actualízate/la_noticia_del_dia_/09-09-10.

16. Corzo JE, Gómez JM. Otros efectos adversos del tratamiento antirretrovírico. Efectos adversos del tratamiento antirretrovírico. Madrid: Scientific Communication Management, S.L. En: Lozano F, Viciana P, editores; 2003. p. 247-54.